SCHEMBL4548949

SCHEMBL4548949

CN1CCN(c2ccc(NC(=O)c3cccc4cc(Oc5ncnc6[nH]ccc56)ccc34)cc2F)CC1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.65
EGFR P00533 4/20 0.56
JAK2 O60674 2/20 0.56
JAK1 P23458 2/20 0.56
JAK3 P52333 2/20 0.56
BTK Q06187 2/20 0.56
LRRK2 Q5S007 1/20 0.56
MAP3K7 O43318 2/20 0.52
MET P08581 4/20 0.49
PTK2 Q05397 1/20 0.47
FLT1 P17948 1/20 0.47
FLT4 P35916 1/20 0.47
MAP4K2 Q12851 1/20 0.46
BRAF P15056 1/20 0.45
MAPK14 Q16539 1/20 0.45
TNNI3K Q59H18 1/20 0.45
FGFR1 P11362 1/20 0.44
FGFR2 P21802 1/20 0.44
FGFR3 P22607 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548914 0.81 KDR (0.83) KDRMETFLT1FLT4BRAF
SCHEMBL4548941 0.81 KDR (0.77) KDRMETFLT1FLT4BRAF
SCHEMBL4548913 0.81 KDR (0.83) KDRMETFLT1FLT4BRAF
SCHEMBL4548921 0.81 KDR (0.79) KDRMETFLT1FLT4BRAF
SCHEMBL4548928 0.81 KDR (0.74) KDRMETFLT1FLT4BRAF
SCHEMBL4548912 0.80 KDR (0.84) KDRFLT1FLT4BRAFMAPK14
SCHEMBL4548955 0.80 KDR (0.59) KDRMAP3K7METFLT1FLT4
SCHEMBL4548917 0.79 KDR (0.75) KDRMETFLT1FLT4BRAF
SCHEMBL4548939 0.79 KDR (0.77) KDRMETFLT1FLT4BRAF
SCHEMBL4812261 0.79 KDR (1.00) KDRMETFLT1FLT4BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885EGFR 129/4885JAK2 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.